Assistant Professor, Psychiatry, University of Pittsburgh School of Medicine
Psychiatry
Dr. Francis E. Lotrich, MD
|
|
Give Review
Francis E. Lotrich works in the field of Psychiatry. He attended Oregon Health & Science University School of Medicine. Francis Lotrich is a published doctor as well. He has 47 publications published. The latest was: Genetic differences in behavioral sensitivity to a neuroactive steroid. He accepts all Medicare patients.
Publications
- Predictors and Moderators of Remission With Aripiprazole Augmentation in Treatment-Resistant Late-Life Depression: An Analysis of the IRL-GRey Randomized Clinical Trial.
- Antidepressant Response Trajectories and Associated Clinical Prognostic Factors Among Older Adults.
- Effect of 2 Psychotherapies on Depression and Disease Activity in Pediatric Crohn's Disease.
- Fibromyalgia Symptoms and Cirrhosis.
- Inflammation, Psychiatric Symptoms, and Opioid Use Are Associated With Pain and Disability in Patients With Cirrhosis.
- Inflammatory cytokine-associated depression.
- Brain-derived neurotrophic factor levels in late-life depression and comorbid mild cognitive impairment: a longitudinal study.
- Anger induced by interferon-alpha is moderated by ratio of arachidonic acid to omega-3 fatty acids.
- The relationship between interleukin-1 receptor antagonist and cognitive function in older adults with Bipolar disorder.
- Common Selective Serotonin Reuptake Inhibitor Side Effects in Older Adults Associated with Genetic Polymorphisms in the Serotonin Transporter and Receptors: Data from ...
- Elevated ratio of arachidonic acid to long-chain omega-3 fatty acids predicts depression development following interferon-alpha treatment: relationship with interleuki...
- Escitalopram reduces attentional performance in anxious older adults with high-expression genetic variants at serotonin 2A and 1B receptors.
- Brain-Derived Neurotrophic Factor Serum Levels and Genotype: Association with Depression during Interferon-? Treatment.
- Gene-environment interactions in geriatric depression.
- Preventing depression in later life: state of the art and science circa 2011.
- IL28B Polymorphism Is Associated with Both Side Effects and Clearance of Hepatitis C During Interferon-Alpha Therapy.
- Labile anger during interferon alfa treatment is associated with a polymorphism in tumor necrosis factor alpha.
- Gene-environment interactions and depression.
- Cytokine-induced depression during IFN-alpha treatment: the role of IL-6 and sleep quality.
- Risk for depression during interferon-alpha treatment is affected by the serotonin transporter polymorphism.
- Age, model for end-stage liver disease score, and organ functioning predict posttransplant tacrolimus neurotoxicity.
- Translational research in late-life mood Disorders: implications for future intervention and prevention research.
- Sex steroid hormone gene polymorphisms and Depressive symptoms in women at midlife.
- Relevance of assessing Drug concentration exposure in pharmacogenetic and imaging studies.
- Aging and clinical pharmacology: implications for antidepressants.
- Dextromethorphan-induced delirium and possible methadone interaction.
- Effects of serotonin transporter promoter polymorphisms on serotonin function.
- Utility of sparse concentration sampling for citalopram in elderly clinical trial subjects.
- Genetic differences in behavioral sensitivity to a neuroactive steroid.
- Preliminary findings regarding proinflammatory markers and brain-derived neurotrophic factor among adolescents with Bipolar spectrum disorders.
- Depression symptoms, low-grade inflammatory activity, and new targets for clinical intervention.
- Predicting 6-week treatment response to escitalopram pharmacotherapy in late-life major depressive Disorder.
- Association of the serotonin transporter gene-linked polymorphic region (5-HTTLPR) genotype with depression in elderly persons after hip fracture.
- Achieving long-term optimal outcomes in geriatric depression and anxiety.
- Polymorphism of the serotonin transporter: implications for the use of selective serotonin reuptake inhibitors.
- Serotonin transporter promoter polymorphism in African Americans : allele frequencies and implications for treatment.
- Neuroendocrine response to intravenous citalopram in healthy control subjects: pharmacokinetic influences.
- Serotonin transporter genotype interacts with paroxetine plasma levels to influence depression treatment response in geriatric patients.
- Depression following pegylated interferon-alpha: characteristics and vulnerability.
- Candidate genes for antidepressant response to selective serotonin reuptake inhibitors.
- Poor sleep quality predicts onset of either Major depression or subsyndromal depression with irritability during interferon-alpha treatment.
- Major depression during interferon-alpha treatment: vulnerability and prevention.
- Serotonin transporter triallelic genotype and response to citalopram and risperidone in dementia with behavioral symptoms.
- The role of inflammation in the pathophysiology of depression: different treatments and their effects.
- Meta-analysis of serotonin transporter polymorphisms and affective Disorders.
- Use of antidepressants in late-life depression.
Schools
Oregon Health Sciences University
Procedures Preformed
- Electroconvulsive Therapy (ECT)
- Psychiatric Medication Therapy
Conditions Treated
- Bipolar Disorder
- Borderline Personality Disorder
- Major Depressive Disorder
- Nondependent Alcohol Abuse
- View All
Doctors Specialties
- Psychiatry
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Blue Card PPO
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Community Blue PPO
- Choice Care PPO
- Medicaid
- Medicare MCR
- MultiPlan PPO
- PHCS Network PPO
- UPMC Health Plan
Education
-
University of Pittsburgh Medical Center -
Oregon Health & Science University School of Medicine
Hospital
-
UPMC Presbyterian Shadyside -
UPMC Passavant
Drug Facts
| NPI NUMBER | 1104890359 | |
| NPPES Provider LastName | LOTRICH | |
| NPPES Provider FirstName | FRANCIS | |
| NPPES Provider ZIPCode | 152132593 | |
| NPPES Provider State | PA | |
| Specialty Description | Psychiatry | |
| Total Claim Count | 262.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1104890359 |
| Last Name Of The Provider | LOTRICH |
| First Name Of The Provider | FRANCIS |
| View All |
Similar Doctors
|
|
Dr. Stuart D. Hirsch, MD |
|
|
Dr. Alan J. Reis, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David L. Johnson, MD |
|
|
Dr. Karen A. Kelly, MD |
|
|
Dr. Ewa Mickiewicz-Marcinkowska, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Katherine L. Wisner, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Paul Blastos, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Craig S. Coleman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Melissa Muniz-Cohen, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Joseph T. Tasosa, MD
This Doctor is OpenDoctor Recommended.
|